Janssen announced that it would accelerate the development of COVID-19 vaccine development. The press statement said that it accelerated the Phase 1/2a trial of the SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
The trial is intended to evaluate the safety, reactogenicity (response to vaccination), and immunogenicity (immune response) of SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
The company has also announced that the discussions with National Institutes of Allergy and Infectious Diseases are in progress and the company is planning to start the Phase 3 trial ahead of schedule.
"Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to accelerate further the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant," said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.
The company earlier mentioned that it is committed to supplying 1 billion doses of vaccine through the course of 2021. Janssen is working on various collaborations to achieve this target. Earlier, the company has announced that it is collaborating with Emergent BioSolutions, Inc. to support the manufacturing of the vaccine. The company is also planning to scale up the manufacturing capabilities of its sites outside the US.